{"text": ["Roche's", "(RHHBY)", "BLA", "for", "Lymphoma", "Drug", "Gets", "Priority", "Review"], "created_at": "2019-02-19 21:41:09"}
{"text": ["2", "Pharma", "Stocks", "in", "the", "Middle", "of", "an", "Oncology", "Sales", "Explosion"], "created_at": "2019-02-19 16:11:17"}
{"text": ["2", "Pharma", "Stocks", "in", "the", "Middle", "of", "an", "Oncology", "Sales", "Explosion"], "created_at": "2019-02-19 16:11:17"}
{"text": ["2", "Pharma", "Stocks", "in", "the", "Middle", "of", "an", "Oncology", "Sales", "Explosion"], "created_at": "2019-02-19 14:29:00"}
{"text": ["AbbVie", "stock", "up", "0.2%", "after", "FDA", "grants", "upadacitinib", "priority", "review", "status"], "created_at": "2019-02-19 13:56:00"}
{"text": ["AbbVie", "Announces", "New", "Drug", "Application", "Accepted", "for", "Priority", "Review", "by", "U.S.", "FDA", "for", "Upadacitinib", "for", "Treatment", "of", "Moderate", "to", "Severe", "Rheumatoid", "Arthritis"], "created_at": "2019-02-19 13:31:00"}
